ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 12 (3) 483-495    DOI: 10.1677/erc.1.00804
Copyright © 2005 by the Society for Endocrinology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Medina, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Medina, D.

REVIEW

Mammary developmental fate and breast cancer risk

Daniel Medina

Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA

(Requests for offprints should be addressed to D Medina; dmedina{at}bcm.tmc.edu)

The ovarian hormones, estrogen and progesterone, play a pivotal role in normal and neoplastic development of the mammary gland. These hormones have a paradoxical role as long duration of estrogen and progesterone are associated with increased breast cancer risk, while short duration of pregnancy level doses are associated with a reduced breast cancer risk. The protective effects of estrogen and progesterone, as well as pregnancy, have been extensively studied in animal models. Recent studies have demonstrated that these hormones induce alterations in gene expression in the mammary epithelial cells which persist for a long time after the hormones are withdrawn from the host. It is postulated that hormones induce a switch in mammary developmental fate which decreases the risk of breast cancer over the lifetime of the host. Some of the possible cellular pathways persistently altered by short term hormone exposure are a decrease in growth factors and an increase in apoptosis. The expression of these genes, in turn, may be affected by alterations in genes regulating chromatin remodeling. The relative contributions of host-mediated factors and mammary cell intrinsic factors remain to be determined. The current studies have moved this research area from the biological to the molecular realm and offer the potential for directing prevention efforts at specific molecular targets.




This article has been cited by other articles:


Home page
Am J EpidemiolHome page
A. Lukanova, R. Andersson, M. Wulff, A. Zeleniuch-Jacquotte, K. Grankvist, L. Dossus, Y. Afanasyeva, R. Johansson, A. A. Arslan, P. Lenner, et al.
Human Chorionic Gonadotropin and Alpha-Fetoprotein Concentrations in Pregnancy and Maternal Risk of Breast Cancer: A Nested Case-Control Study
Am. J. Epidemiol., December 1, 2008; 168(11): 1284 - 1291.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
S. Y. Lee, M. L. Palmer, P. J. Maniak, S. H. Jang, P. D. Ryu, and S. M. O'Grady
P2Y receptor regulation of sodium transport in human mammary epithelial cells
Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1472 - C1480.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Ning, B. Hoang, A. G. P. Schuller, T. P. Cominski, M.-S. Hsu, T. L. Wood, and J. E. Pintar
Delayed Mammary Gland Involution in Mice with Mutation of the Insulin-Like Growth Factor Binding Protein 5 Gene
Endocrinology, May 1, 2007; 148(5): 2138 - 2147.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
L. C. Hartmann, T. R. Milanese, C. M. Vachon, and R. A. Vierkant
Response: Re: Age-Related Lobular Involution and Risk of Breast Cancer
J Natl Cancer Inst, April 4, 2007; 99(7): 572 - 572.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. Ferretti, A. Felici, and F. Cognetti
Pregnancy Levels of Estrogen and Progesterone: The Double-Edged Sword
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 634 - 634.
[Full Text] [PDF]


Home page
Nucleic Acids ResHome page
D. Zhou, J. j. Ye, Y. Li, K. Lui, and S. Chen
The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha
Nucleic Acids Res., November 6, 2006; 34(20): 5974 - 5986.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
L. Hilakivi-Clarke, A. Shajahan, B. Yu, and S. de Assis
Differentiation of Mammary Gland as a Mechanism to Reduce Breast Cancer Risk
J. Nutr., October 1, 2006; 136(10): 2697S - 2699S.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. Aneja, J. Zhou, B. Zhou, R. Chandra, and H. C. Joshi
Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice.
Mol. Cancer Ther., September 1, 2006; 5(9): 2366 - 2377.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
C. Manhes, C. Kayser, P. Bertheau, B. Kelder, J. J Kopchick, P. A Kelly, P. Touraine, and V. Goffin
Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma.
J. Endocrinol., August 1, 2006; 190(2): 271 - 285.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society for Endocrinology.